In vitro sensitivity of Kaposi's sarcoma cells to various chemotherapeutic agents including acyclic nucleoside phosphonates

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 3, 1999, Pages 129-134

  Simonart, Thierry ^a   Andrei, Graciela ^b   Parent, Dominique ^a   Van Vooren, Jean Paul ^a   De Clercq, Erik ^b   Snoeck, Robert ^b  

^a ERASME HOSPITAL   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic nucleoside phosphonate; Cancer; Kaposi's sarcoma; Proliferation

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CIDOFOVIR; CYTARABINE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE; VIRUS DNA;

ARTICLE; CELL GROWTH; CELL STIMULATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KAPOSI SARCOMA; MANAGEMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0033031812     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000304     Document Type: Article

References (33)

1. Andrei G, Snoeck R, Schols D, Goubau P, Desmyter J & De Clercq E (1991) Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. European Journal of Clinical Microbiology & Infectious Diseases 10:1026-1033.
2. Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS & Lietman PS (1997) Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. Journal of Infectious Diseases 176:406-413.
3. Benelli R, Repetto L, Carlone S, Parravicini C & Albini A (1994) Establishment and characterization of two new Kaposi's sacoma cell cultures from an AIDS and a non-AIDS patient. Research in Virology 145:251-259.
4. Blankaert D, Simonart T, Van Vooren JP, Parent D, Liesnard C, Farber CM, Marique T & Werenne J (1998) Constitutive release of metalloproteinase-9 (92-kDa type IV collagenase) by Kaposi's sarcoma cells. Journal of Acquired Immune Deficiency Syndromes 18:203-209.
5. Boshoff, C, Whitby D, Hatziioannon T, Fisher C, van der Walt J, Hatzakis A, Weiss R & Schultz T (1995) Kaposi's sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345:1043-1044.
6. Calonje E & Wilson-Jones E (1997) Vascular tumors. Tumors and tumor-like conditions of blood vessels and lymphatics. In Lever's Histopathology of the Skin, pp. 889-932. Philadelphia, Lippincott-Raven.
7. Costagliola D & Mary-Krause M (1995) Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Lancet 346:578.
8. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowless DM & Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
9. Corbeil J, Evans LA, Vasak E & Cooper DA (1991) Culture and properties of cells derived from Kaposi's sarcoma. Journal of Immunology 146:2972-2976.
10. De Thier F, Simonart T, Hermans P, André J, Van Vooren JP & Noel JC (1999) Early and late stage Kaposi's sarcoma lesions exhibit similar proliferation fraction. American Journal of Dermatopathology 21:25-27.
11. Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P, Larsson L, Beaver B, Wong-Staal F & Gallo RC (1989) AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243:223-226.
12. Ensoli B, Gendelman R, Markham PD, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN & Gallo RC (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371:674-680.
13. Ferguson PJ & Cheng Y (1989) Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Research 49:1148-1153.
14. Gallo RC (1998) The enigmas of Kaposi's sarcoma. Science 282:1837-1839.
15. Gupta S, Aggarwal S & Nakamura S (1998) A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: a survival molecule? Journal of Clinical Immunology 18:256-263.
16. Hammoud Z, Parenti DM & Simon GL (1998) Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clinical Infectious Diseases 26:1233.
17. Hitchcock MJM, Jaffe HS, Martin JC & Stagg RJ (1996) Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chemistry & Chemotherapy 7:115-127.
18. Jones J, Hanson D, Chu S, Ward J & Jaffe WH (1995) AIDS-associated Kaposi's sarcoma. Science 267:1078-1079.
19. Kaaya EE, Parravicini C, Ordonez C, Gendelman R, Berti E, Gallo RC & Biberfeld P (1995) Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. Journal of Acquired Immune Deficiency Syndromes 10:295-305.
20. Kedes DH & Ganem D (1997) Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Journal of Clinical Investigation 99:2082-2086.
21. Kluger MS, Johnson DR & Pober JS (1997) Mechanism of sustained E-selectin expression in human dermal microvascular endothelial cells. Journal of Immunology 158:887-896.
22. Lebbé C, de Crémoux P, Rybojad M, Costa da Cunha C, Morel P Neyts J & De Clercq E (1997) Antiviral drug susceptibility of human herpesvirus 8. Antimicrobial Agents & Chemotherapy 41:2754-2746.
23. Noel JC, Hermans P, Andre J, Fayt I, Simonart Th, Verhest A, Haot J & Burny A (1996) Herpesvirus-like DNA sequences and Kaposi's sarcoma. Cancer 77:2132-2136.
24. Ozawa S, Yasuda T & Inaba M (1988) Comparison of cellular basis of drug sensitivity of human colon, pancreatic, and renal carcinoma cell lines with that of leukemia cell lines. Cancer Chemotherapy & Pharmacology 22:41-46.
25. Pammer J, Plettenberg A, Weninger W, Diller B, Mildner M, Uthman A, Issing W, Stürlz M & Tschachler E (1996) CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. American Journal of Pathology 148:1387-1396.
26. Robles R, Lugo D, Gee L & Jacobson MA (1999) Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. Journal of Acquired Immune Deficiency Syndromes 20:34-38.
27. Safrin S, Cherrington J & Jaffe HS (1997) Clinical uses of cidofovir. Reviews in Medical Virology 7:145-156.
28. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS & Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. New England Journal of Medicine 298:1321-1327.
29. Simonart T, Noel JC, Liesnard C, Parent D, Heenen M, Brancart F, Van Vooren JP, Farber CM, Blankaert D & Werenne J (1996) Kaposi's sarcoma and herpesvirus 8: a word of caution. Dermatology 193:272.
30. Simonart T, Degraef C, Noel JC, Fokan D, Zhou L, Pradier O, Ducarme M, Schandene L, Van Vooren JP, Parent D & Heenen M (1998a) Overexpression of Bcl-2 in Kaposi's sarcoma-derived cells. Journal of Investigative Dermatology 111:349-353.
31. Simonart T, Noel JC, Van Vooren JP & Parent D (1998b) Role of viral agents in the pathogenesis of Kaposi's sarcoma. Dermatology 196:447-449.
32. Simonart T, Noel JC, De Dobbeleer G, Parent D, Van Vooren JP, De Clercq E & Snoeck R (1998c) Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case. Journal of Medical Virology 55:215-218.
33. Tappero JW, Conant MA, Wolfe SF & Berger TG (1993) Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. Journal of the American Academy of Dermatology 28:371-395.